Psoriatic arthritis
David Liew drdavidliew
2 years 11 months ago
So does PsA affect your capacity to work?
DISCOVER-2 analysis:
It’s presenteeism, not absenteeism which is the issue
PsA pts drag themselves into work, but treating them helps them actually do their job. We need to fund more rheumatologists!
ABST0509 @RADoctor #ACR22 @RheumNow https://t.co/Jnac6mV9O5
Aurelie Najm AurelieRheumo
2 years 11 months ago
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Despite a wealth of treatment options, a number of notable unmet needs remain in PsA, most notably the significant diagnostic delay that many patients endure. We are all aware that those with psoriatic skin disease are the most at risk cohort for PsA. Identifying patients with psoriasis who have, or are at increased risk of PsA, appears to be the low hanging fruit that we just can’t fully seem to grasp.
TheDaoIndex KDAO2011
2 years 11 months ago
Dr Scher shares his algorithm Rx for #PsA in clinical practice #acrreview #acr22 @RheumNow https://t.co/0xB1KwpfW7
Catherine Sims, MD DrCassySims
2 years 11 months ago
Does #COVID19 #vaccine work in #psoriaticarthritis? @RheumNow #ACR22 Abstract #0389
🤚 HR for infection and hospitalization similar between controls and PsA after 2nd vaccination
🤚#Enbrel (OR 2.39) and #JAKi (OR 9.90) higher risk of infection and hospitalization
TheDaoIndex KDAO2011
2 years 11 months ago
Withdrawing IL17i will more likely cause a relapse, but pts will respond when reintroduced -Dr Scher #PsA @rheumnow #acr22 #acrreview https://t.co/FvWVuQGJda
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.
Abbvie
Poster Hall